Live latebreaking news brought to you by our own Sandy $MONG news team! 🟪

🫳🐺🤡

A new #LateBreaking summary from #SCAI2024 evaluates the safety and feasibility of using a new dual mechanism moderate bore Hēlo #PulmonaryEmbolism thrombectomy system.

➡️Read late-breaking science: ow.ly/3QvQ50RHhnl

#InterventionalCardiology #CardioTwitter #PE MyJSCAI

For patients implanted with pacemakers for bradycardia - does routine #echofirst screening for #heartfailure improve clinical outcomes?

Find out when we present #OPTPACE as a #latebreaking trial update at #ESCCongress 2023!

The abstract submission deadline for #FUN24 has passed, but you can still submit #latebreaking abstracts for oral and poster presentations. Hurry, as a limited number of slots are still available. The deadline for late-breaking abstract submission is #June2nd .

Join us at #FUN24 ,

デルタフライ

今後のポイント
11/13あたり　決算

11/21より
ASH latebreaking abstract
サイトオープン
ここまでに明らかとなるか？

さて、どう立ち回るか
考え抜く…

NIF at @ismrm & @SMRT_ISMRM: #LateBreaking : Dr Myrte Strik presenting 'Tracking evolution of multiple sclerosis lesions during medication switch: a quantitative multiparametric 7T MRI approach' supported by MBCIU. Warda T Syeda, PhD Rebecca Glarin Scott Kolbe submissions.mirasmart.com/ISMRM2023/Itin…

Interested in the #prairie #microbiome at #ESA2023 ? Find me at spot 251 tomorrow afternoon in the latebreaking poster session, where my poster’s title has changed but my research has not! Let’s have a chat about prairie microbiomes!

Dr. Estaban Perez (PGY-2) presented a #LateBreaking study in #ATS2024 . His research is part of his doctoral project focusing in the host defense mechanisms against M. tuberculosis🔬🦠.

American Thoracic Society (ATS) #TB

I’m so proud of Dr. Hyejin Park from our Brain AVM lab Eunsu Park UTHealth Houston giving a LateBreaking presentation #ISC24 on her latest discovery, “Macrophage-induced Vascular Smooth Muscle Cell Apoptosis Triggers Intracerebral
Hemorrhage in KRAS-induced bAVM”. Well done!

Breaking: Oral PCSK-9 inhibitor is effective with 60% LDL lowering without important side effects in a short 8 weeks fase 2 study
#ACC23 #pcsk9 #MK0616 #oral #Latebreaking #trial

Just ONE MONTH to go to #BNA2023 !!!
Get #FestivalReady by:
🎟️ booking your place meetings.bna.org.uk/bna2023/reg-an…
📰 submitting your latebreaking abstract (deadline 31 March) meetings.bna.org.uk/bna2023/reg-an…
. Parkinson's UK Brain Association of British Neurologists British Association for Cognitive Neuroscience BAP BNS Neuropathology British Neuropsychiatry Association

Excited to present #KCCQ across the spectrum of EF from #DAPAHF & #DELIVER as a #LateBreaking trial update European Society of Cardiology #HFA2023 ! Many thanks to scottdavidsolomon Muthu Vaduganathan Mikhail Kosiborod & team for the opportunity! See everyone in Prague!

Big theme of this year's #CROI2024 has been long-acting drug formulations - here, latebreaking first data on weekly oral islatravir/lenacapavir. Appears safe and effective - exciting!

Forest Ecology Memes Spring 2024 - Latebreaking submissions

🚀 Ready to make a difference in retina research?

Seize the spotlight at #EURETINA24 in Barcelona! Submit your abstract by 19 June 2024 and unveil your groundbreaking work to global leaders in ophthalmology.

Submit here: ow.ly/AhCW50R5YFM

#EURETINA24 #LATEBREAKING

#LateBreaking #RELEAVE -HF trial showing role of Inter-Atrial shunt in HFrEF vs HFpEF. Congratulations Gregg W. Stone MD 🎉🎊

Thought from experts?

American College of Cardiology #ACC24

The last latebreaking science session 🔥 at #HFA2024 chaired by Prof. Frank Ruschitzka Dept. of Cardiology - University Hospital Zurich CTEC - Zurich University Heart Center and Prof. Maria Costanzo has just started, make sure to join, you won’t regret it. #CardioX #CardioTwitter #HFA_young HFAPresident #20yearsHFA

Read the rapid #InterventionalCardiology takeaways from 5 #LateBreaking studies featured at #EuroPCR 2024—drafted by SCAI experts!

➡️ scai.org/rapid-takeaway…

#CardioTwitter #Research

🔥🔥 #IbrahimAldoss City of Hope presenting #LateBreaking Abstract on #Revumenib for KMT2a rearranged R/R acute leukemia CR/CRh 23%, 1.9 mo to respond, median DOR 6.4months, median OS 8.0 months ASH Syndax